AC Immune
Yuteng Wu currently serves as a Project Leader at AC Immune since October 2021. Prior to this role, Yuteng held positions as a Research Associate at The Francis Crick Institute from April 2019 to September 2021 and as a Postdoctoral Research Scientist at EPFL (École polytechnique fédérale de Lausanne) from December 2016 to March 2019. Yuteng's career began with an Industrial Placement Student role at GSK between October 2011 and September 2012. Yuteng earned a Doctor of Philosophy (PhD) in Chemistry and Chemical Biology from the University of Cambridge from 2013 to 2016 and an MSci in Chemistry with a Year in Industry from Imperial College London from 2008 to 2013.
This person is not in any teams
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.